Calculator
Instructions
Scope
Contact
Applicability criteria for the model
Patients should meet all of the following eligibility criteria:
Patients with confirmed histological diagnosis of neuroendocrine tumor of the pancreas, esophagus, stomach, small intestine, appendix, colon, rectum, or unknown primary
TNM stage IV with documented, unresectable and metastatic disease measurable by computed tomography (CT)
Well-differentiated (G1/G2) tumors according to WHO classification
Ki-67≤20%
The patient is about to start monotherapy with somatostatin analogues (Sandostatin LAR or Lanreotide Autogel), with antiproliferative objective, with the intention of holding it until progression
Absence of potentially curable metastases
No other synchronous metastatic malignancy
Ok, go ahead
Not eligible
Por favor, espere